Physician profile
Angela Torchia
NPI 1447623723
$1,795.03
in general payments reported to CMS, 2019-2025
19 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $444 · 2024: $763 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.67 |
| Education | $366.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $594.29 | 2023-2025 | Jakafi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $190.86 | 2024-2025 | Tagrisso, Calquence, Imfinzi |
| Lilly USA, LLC | $150.18 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $120.83 | 2023 | Padcev |
| Janssen Biotech, INC. | $112.01 | 2024 | Darzalex, Carvykti, Tecvayli |
| Stemline Therapeutics INC. | $108.77 | 2023 | Orserdu |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Genzyme Corporation | $78.11 | 2025 | |
| Celgene Corporation | $54.67 | 2023 | Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $52.71 | 2024-2025 | Opdivo, Opdualag |
| Pfizer INC. | $52.29 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.89 | 2024-2025 | Fruzaqla, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $25.03 | 2024 | Libtayo |
| Adc Therapeutics America, INC. | $23.20 | 2023 | |
| Gilead Sciences, INC. | $22.05 | 2023 | Trodelvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.84 | 2024 | |
| Beigene USA, INC. | $19.00 | 2024 | Tevimbra |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Merck Sharp & Dohme LLC | $14.34 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Torchia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.